IDXX · NASDAQ · STOCK
Idexx Laboratories (IDXX) Stock Analysis
$518.01
52W $500.61 – $769.98
59/100
$40.86B
36.4
1.55
Is IDXX Bullish or Bearish?
Bullish.
Innellis AI committee rates Idexx Laboratories (IDXX) Buy with a composite score of 59/100
, based on 5 analysts with 60% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +16.41 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -3.59 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — 5 consecutive earnings beats -- consistent execution. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 72.0% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 36.0 is moderate-to-rich — Value
- Price-to-book of 33.7x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical
- News sentiment is negative (-0.33 across 3 articles, 14d) — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
59/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 41%
of 192 Healthcare peers
Value Analyst
neutral
48
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 72.0% shows genuine earnings power backing the valuation
− P/E of 36.0 is moderate-to-rich
Growth Analyst
bullish
77
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
56
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
47
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.33 across 3 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 58.6 to 58.6.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
49.6
Neutral
MACD Histogram
0.841
Bullish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Mixed
Support
$501.15
Resistance
$580.88
Bollinger %B
0.53
Inside Bands
Price vs Moving Averages
EMA 9
$517.13
Above
EMA 21
$520.85
Below
EMA 50
$532.45
Below
EMA 200
$567.94
Below
Fundamental Analysis
Valuation
21
Growth
83
Profitability
100
Financial Health
61
Cash Flow
70
Valuation
P/E Ratio
36.4×
P/B Ratio
25.73×
PEG Ratio
2.06
Dividend Yield
0.00%
52W High
$769.98
52W Low
$500.61
Quality & Growth
ROE
6599.4%
ROA
3161.9%
Gross Margin
6244.6%
Operating Margin
3203.5%
Revenue Growth YoY
—
Debt / Equity
0.68
AI Fundamental Assessment
P/E ratio of 36.4 (rich relative to a 15-40x range); Price-to-book of 25.7x; PEG ratio of 2.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 66.0%; Return on assets of 31.6%; Net margin of 25.0%; Gross margin of 62.4%; Current ratio of 1.17 (tight short-term liquidity); Debt-to-equity of 0.68; Free cash flow per share is positive (15.61); Most recent quarter beat estimates by 6.2%; 5 consecutive earnings beats; EPS growth accelerating (+12.7% -> +23.1% QoQ); Average YoY EPS growth of 17.6%; Analyst estimates rising over recent quarters
Get the Full IDXX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →